Regeneron Pharmaceuticals Inc (REGN) WACC Analysis

As of May 27, 2025, Regeneron Pharmaceuticals Inc (REGN) carries a Weighted Average Cost of Capital (WACC) of 9.6%. WACC reflects the blended rate Regeneron Pharmaceuticals Inc must pay to both equity and debt holders.

Within that, the cost of equity is 8.6%, the cost of debt is 4.0%, and the effective tax rate is 7.8%.

Breakdown of WACC Components

• Long-term bond rate: 3.9% – 4.4%
• Equity market risk premium: 4.6% – 5.6%
• Adjusted beta: 1.03 – 1.11
• Additional risk adjustment: 0.0% – 0.5%
• Debt-to-equity ratio: 0.04

What It Means for Investors

With a selected WACC of 9.6%, Regeneron Pharmaceuticals Inc must ensure any new investment returns exceed this threshold to generate shareholder value. This level reflects a moderate financing cost structure.